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Abstract Endothelial colony-forming cells (ECFC) are
grown from circulating CD34? progenitors present in adult
peripheral blood, but during in vitro expansion part of the
cells lose CD34. To evaluate whether the regulation of
CD34 characterizes the angiogenic phenotypical features
of PB-ECFCs, we investigated the properties of CD34?
and CD34- ECFCs with respect to their ability to form
capillary-like tubes in 3D fibrin matrices, tip-cell gene
expression, and barrier integrity. Selection of CD34? and
CD34- ECFCs from subcultured ECFCs was accomplished
by magnetic sorting (FACS: CD34?: 95 % pos; CD34-:
99 % neg). Both fractions proliferated at same rate, while
CD34? ECFCs exhibited higher tube-forming capacity and
tip-cell gene expression than CD34- cells. However, dur-
ing cell culture CD34- cells re-expressed CD34. Cell-
seeding density, cell–cell contact formation, and serum
supplements modulated CD34 expression. CD34 expres-
sion in ECFCs was strongly suppressed by newborn calf
serum. Stimulation with FGF-2, VEGF, or HGF prepared
in medium supplemented with 3 % albumin did not change
CD34 mRNA or surface expression. Silencing of CD34
with siRNA resulted in strengthening of cell–cell contacts
and increased barrier function of ECFC monolayers as
measured by ECIS. Furthermore, CD34 siRNA reduced
tube formation by ECFC, but did not affect tip-cell gene
expression. These findings demonstrate that CD34? and
CD34- cells are different phenotypes of similar cells and
that CD34 (1) can be regulated in ECFC; (2) is positively
involved in capillary-like sprout formation; (3) is associ-
ated but not causally related to tip-cell gene expression;
and (4) can affect endothelial barrier function.
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Adequate regeneration of the tissue affected by ischemic
insult relies on efficient angiogenesis that can be facilitated
by tissue engineering or cell-based therapeutics involving
endothelial cells (ECs). Endothelial cells from different
vascular beds differ in their angiogenic ability to induce
neovascularization in vivo [1]. Therefore, selection of an
adequate EC type is a prerequisite step for successful
construction of tissue-engineered vascular constructs.
Endothelial colony-forming cells (ECFCs) are considered
as the most suitable ECs type for regenerative angiogenesis
[2]. These cells, also named as late outgrowth endothelial
progenitor cells (EPCs) or blood-outgrowth endothelial cells
(BOECs), differ from the early outgrowth CD14?/CD45?
EPC which originate from the myeloid/monocytic lineage
and participate in vascular regeneration in a paracrine fash-
ion [3]. The ECFCs, which can be obtained from cord or
peripheral blood, exhibit pronounced vascularization ability
in vivo by physically incorporating into newly formed blood
vessels [4]. In particular, their neovascularization potency is
accentuated in combination with stem/progenitors cells like
mesenchymal stem cells or adipose-derived stem cells [5].
Previous studies revealed that ECFCs originate from the
blood-derived mononuclear progenitor cell fraction
expressing CD34 among other stem/progenitor cell surface
markers such as CD31 or CD146 [6, 7] and are negative for
CD14 or CD45.
CD34 is a widely used cell surface marker for detection
and isolation of stem and progenitor cells with robust
regenerative potential for therapeutic purposes [8]. CD34 is
a 115-kDa transmembrane glycoprotein rich with O- and
N-glycans. Depending on the cell type, specific modifica-
tions by sulfation or sialylation [9, 10] modulate the
function of the CD34 structure in such manner that dif-
ferent ligands in different environments can interact with
this surface protein [11]. Although the CD34 function
remains elusive, its expression is modulated by growth
factors TGF-b1 and TNF-a [12, 13], by oxygen concen-
tration [14], as well as by several transcription factors [15,
16]. Beside on HSCs [17], it is expressed on small vessel
endothelial cells [18], mast cells [19], epidermal stem cells
[20] as well as tumor cells [21]. In endothelial cells CD34
has been used to identify sprouting endothelial tip cells
during neovascularization in vitro [22] and in vivo [21–23].
Previous publications on other cells reported that CD34
modulates cyto-adhesion [24–26] and cell shape [27], or is
critically involved in L-selectin-mediated transendothelial
migration of T-lymphocytes in high venular endothelia [28,
29]. However, the function of CD34 remains still obscure.
When ECFCs are propagated in culture, they retain
stable expression of endothelial specific markers on their
surface, but CD34 declines during serial propagation [30].
Monolayers of peripheral blood-derived ECFCs (PB-
ECFCs) comprise mixture of cells that do or do not express
CD34 on cell surface implying that phenotypical differences
might exist between CD34? and CD34- cells. Previous
reports that ECFCs which originate from CD34? colonies
exhibit reduced vascularization properties than the cells
isolated fromCD34-ECFCs colonies [31] further underpins
the necessity to investigate the angiogenic features of
CD34? and CD34- ECFC. It might be that the CD34
expression in ECFCs marks a specific state of an endothelial
phenotype that might have different angiogenic properties.
Therefore, we investigated whether the regulation of
CD34 characterizes the angiogenic phenotypical features
of PB-ECFCs. Findings presented in this study revealed
that the CD34 expression is inducible and regulated in PB-
ECFCs by the state of confluency and serum factors in the
growth medium. By separation of CD34? and CD34- cells
and silencing of CD34 with siRNA, we subsequently
investigated the contribution of CD34 during the formation
of endothelial tubules in a 3D-fbrin matrix, the expression
of tip-cell-associated genes, and the endothelial barrier
function of ECFCs’ monolayers.
Materials and methods
Cell culture
Peripheral blood-derived ECFCs were isolated, expanded,
and the endothelial-phenotype-confirmed as previously
described [30]. Briefly, the mononuclear cells (MNC)
obtained from adult peripheral blood were plated in EGM-2
medium (Lonza,Walkersville,MD,USA) supplementedwith
10 % platelet lysate (PL-EGM) and after 10 days the first
ECFC colonies emerged. The isolated cells were
immunophenotypically characterized by flow cytometry (FC)
and were positive for CD31, vWF, CD34, CD144, CD309,
and negative for CD14, CD45, and CD133 [30]. For experi-
mental purposes, the cells were also expanded for 1–2 pas-
sages in complete medium (CMi) composed ofM199 (Lonza,
Verviers, Belgium) supplemented, 10 % newborn calf serum
(NBCS), 10 % human serum (HS), 20 lg/mL endothelial
cell-growth factor, 2 mM L-glutamine, penicillin/strepto-
mycin (100 U/mL/100 lg/mL), and 5 U/mL heparin.
Magnetic separation and tube formation assay
Separation of PB-ECFCs on CD34? and CD34- cells was
performed using CD34 MicroBead Kit (clone QBEND/10,
#130-046-703, Miltenyi Biotech BV, the Netherlands)
according manufacturers’ protocol.
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To increase the purity of yielded CD34 positive and
negative fractions, the cells were twice passed through LS
columns and the efficiency of separation was evaluated by
flow cytometry (FC) using PE or FITC labeled mouse anti-
human CD34 antibody which recognizes different epitope
than QBend-10 (clone 581, #555822, BD Biosciences, the
Netherlands). Data were analyzed using the FCS Express 4
software package (DeNovo Software, Toronto, Ontario,
Canada). The efficiency of separation was also evaluated
by determination of the mRNA levels of CD34 in positive
and negative fractions by qRT-PCR. After separation, the
CD34? and CD34- cells were used for experimental pur-
poses. For assessment of sprouting ability of CD34? and
CD34- PB-ECFCs, 20,000 cells positive or negative for
CD34 antigen were seeded on 3D human fibrin matrices
prepared as previously described [32]. Following overnight
incubation in M199 (Lonza, Verviers, Belgium) supple-
mented with 10 % inactivated human serum and 10 %
newborn calf serum, tube formation was induced by stim-
ulating the cells with combination of 25 ng/mL vascular
endothelial factor-A (VEGF-A) ? 10 ng/mL fibroblast
growth factor-2 (FGF-2). All growth factors were pur-
chased from RELIATech GmbH, Wolfenbuttel, Germany.
After 48-h stimulation, the cells were fixed with 2 %
paraformaldehyde/HBSS, and quantification of the length
of formed tube-like structures was performed using Opti-
mas image analysis software as previously described [32].
The tube formation ability of PB-ECFCs of three different
donors was each determined in triplicate wells.
Proliferation ability of CD341 and CD342 cells
For short-term proliferation assays 500 CD34? or CD34-
cells/cm2 were seeded onto 12-well plate precoated with
rat-tail collagen type I (BD Biosciences, Erebodegem,
Belgium) in PL-EGM. Renewal of culture medium was
performed every other day. After 7 days in culture, the
cells were washed with PBS and fixed with pre-warmth
2 % paraformaldehyde/HBSS. DAPI Vectashield Hardset
(Vector Laboratories Ltd, BrunschwigChemie, the
Netherlands) was used to visualize the cell nuclei, and five
pictures from each well were taken using phase contrast
microscopy. The number of cells was determined using
ImageJ software, and the calculations for population dou-
bling was performed as previously described [33].
Re-expression of CD34 during cell culture
To investigate whether CD34 is re-expressed in CD34-
PB-ECFCs that were obtained after the magnetic separa-
tion from the cell cultures of four different donors, the
CD34- cells were seeded in CMi medium (CD34- CMi
cells) or in PL-EGM medium (CD34- PL cells) and left to
reach confluence (Online resource, Supp. Figure 1).
Part of CD34- PB-ECFCs was also incubated in M199
supplemented with 3 % pyrogen-free human serum albu-
min (3 % HSA, Sanquin, Amsterdam, the Netherlands) for
24 h. The CD34 expression was evaluated by FC. After
3–4 days in cell culture CD34- CMi cells and CD34- PL
cells were harvested for experimental purposes. The CD34
expression in CD34- CMi cells and CD34- PL cells was
evaluated by qRT-PCR and FC. To investigate the
expression of tip-cell-associated genes in CD34- PL cells
that re-express CD34, the CD34- PL ECFCs were sepa-
rated on CD34? and CD34- cells by magnetic separation
as previously described and qRT-PCR was performed.
Effect of serum supplements and growth factors
on CD34 expression in PB-ECFCs
For assessment of the effect of NBCS on CD34 expression
in PB-ECFCs over period of 24 h, the cells were incubated
with 10 % NBCS, 10 % PL, 10 % NBCS ? 10 % PL, and
3 % HSA all prepared in M199. The cells were harvested
after 9-, 12-, and 24-h incubation period, and the CD34
mRNA levels were evaluated by qRT-PCR.
To investigate the expression of CD34 in cell cultures of
PB-ECFCs in CMi and PL-EGM, the ECFCs obtained from
different donors were expanded for two passages in CMi or
PL-EGM medium, and the CD34 surface expression was
evaluated by FC.
The effect of pro-angiogenic growth factors and 10 %
PL on CD34 expression in PB-ECFCs was investigated
after 24-h incubation of the cells with 10 ng/mL fibroblast
growth factor-2 (FGF-2, 25 ng/mL), vascular endothelial
factor-A (VEGF-A, 10 ng/mL), hepatocyte growth fac-
tor(HGF, 10 ng/mL) and 10 % PL all prepared in M199
supplemented with 3 % HSA. In parallel the cells were also
incubated with 10 ng/mL FGF-2, 25 ng/mL VEGF-A,
10 ng/mL HGF, and 10 ng/mL TNF-a all prepared in
EBM-2 medium supplemented with 5 % PL for 24 h. Cells
incubated only in M199 ? 3 % HSA or EBM-2 ? 5 % PL
served as control. The mRNA and surface expression of
CD34 was measured by qRT-PCR and FC.
Effect of cell-seeding density and proliferation
on CD34 expression in PB-ECFCs
To investigate whether cell density regulates the CD34
expression during passage of ECFCs, the cells from four
individual donors were seeded on rat-tail collagen type I
pre-coated six-well plates in PL-EGM at densities of 100,
500, 1000, and 2000 cells/cm2. The gene and surface
expression of CD34 was evaluated by qRT-PCR and FC
after 5 and 6 days of proliferation.
Angiogenesis (2016) 19:325–338 327
123
Proliferation assay was performed by seeding 100, 500,
1000, and 2000 cells/cm2 in 8 wells per seeding condition
using 24-well plate. To enumerate the number of cells in
cell cultures after 5 and 6 days of proliferation, the cells
were fixed and stained with DAPI Vectashield Hardset
(Vector Laboratories Ltd, BrunschwigChemie, the
Netherlands). Image acquisition was performed using 4D-
digital imaging microscope (DIM) by taking five images
per well, and the cell number was calculated using ImageJ
software.
siRNA transfection and tube formation assay
To investigate the involvement of CD34 during sprout
formation in fibrin matrices by PB-ECFCs, the cells were
expanded for one passage in CMi to reduce the expression
of CD34. After reaching confluence, the cells were
expanded at 1:2 ratio and were incubated with ON-TAR-
GET plus human CD34(947) siRNA-SMART pool (#L-
019503-00-0005, Thermo Scientific, the Netherlands) for
silencing CD34 (siRNA CD34 cells) or were incubated
with ON-TARGETplus Non-targeting Pool siRNA (cat.no.
D-001810-10-05,GE Dharmacon, Lafayette, CO) (siRNA
NT cells). Non-transfected cells were used as control. Prior
to transfection experiments, cells were starved for 4 h in
M199 and were transfected using DharmaFECT4 reagent
(Dharmacon). All siRNA and DharmaFECT4 were pre-
pared in M199 ? 10 % inactivated human serum supple-
mented with 10 ng/mL FGF-2 at final concentration of
20 nM. After 24 h of the transfection period the transfec-
tion medium was replaced by fresh PL-EGM medium.
After additional 24 h the cells were detached and seeded on
fibrin matrices as previously described. The transfection
efficiency was evaluated by qRT-PCR and FC prior to
seeding the cells on fibrin matrices. Sprout formation was
initiated by stimulating the cells with combination of
10 ng/mL TNF-a and 10 ng/mL FGF-2 every day during
2-day period. Inhibition of tube formation was accom-
plished by transfecting the PB-ECFCs with siRNAs against
uPA (Hs_PLAU_6 FlexiTube siRNA, cat.no. SI02662135,
QiagenBenelux B.V., the Netherlands) which was prepared
using the above described procedure. The tube formation
ability of PB-ECFCs of four donors was determined in
quadruplicate wells. Quantification of the length of formed
tube-like structures was performed as previously described.
siRNA transfection and endothelial barrier function
assays
To investigate the involvement of CD34 in the mainte-
nance of barrier function, the PB-ECFCs from three dif-
ferent donors were transfected with siRNA against CD34
or non-targeting siRNA as described in the previous
section. Endothelial barrier function was evaluated with
electric cell substrate impedance sensing (ECIS) as previ-
ously reported [34]. Briefly, the siRNA CD34 and siRNA
NT cells were seeded in 1:1 density on gelatin-coated ECIS
arrays, each containing 96 wells with 10 gold electrodes
per well (96W10idf plates, Applied Biophysics, Troy, NY)
in M199 ? 10 % HSi ? 10 ng/mL FGF-2. Resistance was
measured at multiple frequencies to allow for calculation of
resistance attributable to cell–cell adhesion (Rb) and to
cell–matrix interaction (Alpha) over period of 24 h [34].
Real-time polymerase chain reaction
The total RNA from PB-ECFCs was isolated using RNeasy
MinElute Cleanup Kit (Qiagen, the Netherlands), and the
RNA quality was tested with a NanoDrop 1000 spec-
trophotometer. Copy DNA (cDNA) was synthesized using
the Cloned AMV first-strand cDNA synthesis kit from
Invitrogen. The sequences of primers used for determina-
tion of genes of interest are given in Online resource Supp.
Table 1.
Quantitative RT-PCR was performed using SYBR
Green in an ABI 7500 sequence detection system (Applied
Biosystems, Foster City, USA) and the following protocol:
2 min 50 C, 10 min 95 C and 40 cycles (15 s 95 C,
1 min 60 C) and dissociation curve. The relative expres-
sion levels of target genes were calculated with the
housekeeping gene glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) by following equation as previous
described [35]: D Ct sample = (Ct sample GENE) - (Ct
sample HKG). The relative gene expression = 2 (D Ct
sample 1 - D Ct Sample).
Results
Selection of CD341 and CD342 cells from PB-
ECFCs
While PB-ECFC colonies arise from CD34? cells [6],
during subculturing both CD34? and CD34- ECFCs are
encountered. To investigate whether CD34?-subcultured
ECFCs are a better cell source for tissue engineering than
their CD34- counterparts, we compared the proliferation
capacity of CD34? with that of CD34- cells as well as
their sprouting ability in a 3D-fibrin matrix. Confluent
cultures of PB-ECFCs from four donors were separated
into CD34? and CD34- cells using CD34 magnetic beads.
After each separation, the purity of yielded cell fraction
was evaluated by flow cytometry (FC). Two sequential
separations steps yielded highly purified CD34?
(95 % ± 0.8) and CD34- (99 % ± 0.8) cell fractions
(Online resource Supp. Figure 2).
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During the course of 7 days both cell fractions prolif-
erated at same rate indicating that CD34? ECFCs did not
differ to CD34- ECFCs with respect to the proliferation
ability (Fig. 1a).
Stimulation with a combination of VEGF-A and FGF-2
induced sprout formation in fibrin matrices by both cell
fractions (Fig. 1b, c). Comparison of sprouting ability of
CD34? and CD34- cells revealed CD34? ECFCs formed
more sprouting structures than CD34- ones (Fig. 1d).
Previously we demonstrated that sprouting by ECFCs
required u-PA and uPAR and is modulated by PAI-1 [30].
There were no significant differences observed between
CD34? and CD34- ECFCs in the expressions of u-PA
(1.1 ± 0.7), uPAR (1.1 ± 0.3), and PAI-1 (1.5 ± 0.7)
(mean ± SEM, four different donors). Further phenotypi-
cal characterization of CD34? ECFCs unveiled that
CD34? cells displayed an enrichment of genes usually
accepted as markers of tip-cell phenotype (Fig. 1e). These
data suggest that selection of CD34? ECFCs might be
feasible approach to facilitate the initiation of regenerative
angiogenesis in ischemic tissues.
CD341 and CD342 ECFCs are interchangeable
phenotypes
As both CD34? and CD34- ECFCs originate from
mononuclear cell fraction positive for CD34 [6], we won-
dered whether CD34- ECFCs represent a separate lineage
of cells or merely reflect a phenotype, which can re-acquire
CD34 antigen. Therefore, we subsequently investigated
whether the cells in culture that are negative for CD34 can
re-express this protein on mRNA and protein level. Using
magnetic beads the PB-ECFCs from four donors were
separated on CD34? and CD34- ECFCs, and the efficiency
of separation was evaluated by FC (Online resources Supp.
Figure 2).
Both CD34? and CD34- fractions had comparable
expressions of VE-cadherin, CD31, and VEGFR2 mea-
sured by FC, which were the same as in ECFCs before
separation, which confirms the endothelial nature of both
fractions (not shown). After separation, the CD34- ECFCs
were seeded and cultured in PL-EGM (CD34- PL) or CMi
(CD34- CMi) and once the cells reached confluence
(3–4 days), and the number of CD34? cells was quantified
by FC analysis, while in parallel the mRNA levels of CD34
were evaluated by qRT-PCR. The CD34- PL ECFCs re-
expressed significantly more CD34 than the control cells
both at gene and at protein level (Fig. 2a, b).
Incubation of CD34- cells in M199 medium supple-
mented with 3 % human serum albumin (HSA)for 24 h
also induced upregulation of CD34 on the cell surface
(Online resources Supp. Figure 3). This indicates that the
expression of CD34 was reversible.
To investigate whether CD34? ECFCs in the CD34-
fraction that re-expressed CD34 on cell surface are also
characterized by the enrichment of tip-cell-associated
genes (VEGFR2, DLL4, CXCR4, EFNB2, IGFBP3), we
subsequently separated CD34- PL that re-expressed CD34
into positive and negative for CD34 ECFCs and performed
qRT-PCR. Indeed, CD34? ECFCs obtained from CD34-
PL cells that re-expressed CD34 on cell surface also
expressed significantly more mRNA transcripts of the
genes related to tip-cell phenotype (Fig. 2c). This finding is
in line with the data obtained from freshly separated cells
(Fig. 1f).
Unexpectedly, the cells cultured in CMi exhibited only
slight increases in CD34 mRNA and surface antigen levels
compared to the initially seeded CD34- cells (Fig. 2a, b).
This suggests that serum components of the CMi do not
favor the re-expression of CD34 on CD34- ECFCs, indi-
cating that the soluble factors present in serum play a role
in regulation of CD34 in PB-ECFCs.
Serum supplements affect CD34 expression
in confluent ECFCs
We subsequently evaluated which serum supple-
ment(s) might modulate CD34 expression in PB-ECFCs.
To that end we compared platelet lysate and serum used in
CMi, in particular 10 % NBCS and 10 % HS. Confluent
monolayers of PB-ECFCs grown in CMi were transferred
into M199 medium supplemented with 10 % NBCS, 10 %
PL, 10 % NBCS/10 % PL, or 3 % HSA and incubated for
9, 12, and 24 h. In the presence of only 3 % HSA, CD34
mRNA expression increased fivefold within 9 h and
remained constant thereafter (Fig. 3a).
In the presence of PL a slow increase was observed
reaching two- to sixfold after 9 and 24 h, respectively.
However, in the presence of NBCS—a serum component
of CMi, the CD34 mRNA expression remained at the
original low level. Also when NBCS and PL were com-
bined the CD34 mRNA expression remained low (Fig. 3a).
Apparently, NBCS did not stimulate CD34 expression and
had a dominant suppressive effect over PL as well. The
difference between exposure to medium containing NBCS
such as CMi and that to PL was also reflected in the cell
surface expression of CD34 antigen (Fig. 3b).
To evaluate whether pro-angiogenic growth factors and
cytokines might affect the CD34 expression in confluent
PB-ECFCs, we compared their effects both in PB-ECFCs
that were incubated in M-199 supplemented with 3 % HSA
as well as EBM-2 ? 5 % PL. The growth factors FGF-2,
VEGF-A, and HGF did not change CD34 mRNA or surface
antigen expression significantly in both conditions
(Fig. 2c–e). Addition of 5–10 % PL to HSA-containing
medium also did not alter CD34 mRNA expression. The
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inflammatory cytokine TNF-a reduced the mRNA and
antigen expression significantly (Fig. 2d, e), in agreement
with previous finding on endothelial cells [13].
Proliferation and seeding density alter CD34
expression in ECFCs
To investigate whether cell density regulates CD34
expression during passage of ECFCs, the cells from four
individual donors were seeded on rat-tail collagen type I in
PL-EGM at densities of 100, 500, 1000, and 2000 cells/
cm2. The CD34 expression was evaluated after five (D5)
and 6 days (D6) of culturing using PCR and FC. During the
course of proliferation assay, the conditions with 100, 500,
and 1000 cells/cm2 contained significantly more cells at
D6 compared to D5, indicating that the cells continued to
proliferate in 24-h period between the two time points
reaching different levels of confluence (Fig. 4a, Online
resources Supp. Figure 4a–f).
On contrary, at 2000 cells/cm2 at D5 and D6 similar
numbers of cells were counted suggesting that the cell
cultures were confluent and the cells had stopped dividing
(Fig. 4a, Online resources Supp. Figure 4g–h). Before the
start of experiment the percentage of CD34? cells in the
cultures obtained from different donors was 83.3 ± 11.5 %
as measured by FC. Strong reduction in the number of
CD34? cells was observed in the cultures established with
100, 500, and 1000 cells/cm2 at D5 and D6, while a cell-
density-dependent restoration of CD34 content occurred as
most clear in 2000 cells/cm2 cultures (Fig. 4b). These data
indicate that proliferation as well as cell density affects the
regulation of CD34 in ECFCs probably through establish-
ment of cell–cell contacts. Progressive increase in CD34
mRNA levels between D5 and D6 was also observed in all
seeding conditions as measured by qRT-PCR (Fig. 4c),
suggesting that establishment of cell–cell contact also
promotes CD34 transcription irrespectively of proliferation
status of cell cultures.
CD34 alters barrier function of PB-ECFCs
Previous studies reported that CD34 molecules on two
adjacent EC cells play an important role in initiation of
lumen formation in mouse embryo by generation of
Fig. 1 Angiogenic capacity of CD34? PB-ECFCs. a Proliferation
capacity of CD34- (open bar) and CD34? (closed bar) PB-ECFCs
expressed as a mean ± SEM of population doubling. b–c Represen-
tative phase contrast images of sprout formation in fibrin matrices by
CD34- (b) and CD34? (c) ECFCs stimulated with the combination of
VEGF-A and FGF-2. d Quantification of sprouting ability of CD34-
(open bar) and CD34? (closed bar) PB-ECFCs in fibrin matrices.
Data are expressed as a mean ± SEM of mean length of formed
sprouts of four independent experiments each performed with
different donor. e mRNA levels of genes associated with tip-cell
phenotype in CD34? PB-ECFC compared to CD34- cells. Open bar
depict mRNA levels of tip-cell-associated genes in CD34- cells.
Closed bars represent mRNA levels of tip-cell associated genes in
CD34? cells
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repulsive forces that destabilized cell–cell contacts [36].
Considering that disassembling of the continuity of EC
monolayer is one of the first steps in angiogenic sprouting,
we investigate whether silencing of CD34 changes the
barrier properties of ECFC. PB-ECFCs from three donors
were transfected with siRNA targeting CD34. Efficient
silencing of CD34 at the cell surface and gene level was
confirmed by FC and qRT-PCR (Online resources Supp.
Figure 5).
The transfection procedure did not alter the gene
expression levels of CD31 and VE-cadherin, which play an
important role in cell–cell interaction (Fig. 5d).
ECIS measurement over period of 24 h revealed that
silencing of CD34 caused an increase of total resistance of
the ECFC monolayer (Fig. 5a). Quantification at the end of
24-h period confirmed that a significantly higher resistance
was observed in the cell monolayers with silenced CD34
than in the controls, non-transfected cells or the cells
transfected with non-targeting siRNA (Fig. 5b). After
computational modeling of the endothelial electrical
resistance which enables discrimination between cell–cell
and cell–matrix interactions, we detected that the increase
in total endothelial resistance upon silencing of CD34 was
attributable to increased cell–cell interactions (Fig. 5c).
This indicates that CD34 favors the loosening of cell–cell
interaction between PB-ECFCs.
Silencing of CD34 reduces sprout formation ability
of PB-ECFCs
To further evaluate the contribution of CD34 to sprouting,
we assessed the impact of silencing of CD34 expression by
siRNA on sprout formation in fibrin matrices. PB-ECFCs
transfected with siRNA CD34 (siRNA CD34 cells), or non-
Fig. 2 Expression of CD34 in CD34? and CD34- PB-ECFCs
fractions after magnetic separation. a CD34 mRNA levels in CD34-
ECFCs after cell culture in PL-EGM or CMi. Open bar depicts the
CD34 mRNA levels in CD34- ECFCs obtained after separation and
prior the seeding in PL-EGM or CMi. Closed bars represent CD34
mRNA levels in CD34- CMi and CD34- PL cells after 6 days in cell
culture. b Flow cytometry evaluation of the number of CD34? cells in
CD34- ECFCs cultures expanded in CMi or PL-EGM. Data are
expressed as mean ± SEM percentage of cells positive for CD34 in
the cell cultures expanded either in CMi or PL-EGM (closed bars).
The control CD34- cells are depicted with open bar. c mRNA levels
of genes associated with tip-cell phenotype in CD34? and CD34- PB-
ECFCs obtained after magnetic separation of CD34- PL. Open bar
depict mRNA levels of tip-cell associated genes in CD34- cells,
while closed bars represent mRNA levels of same genes in CD34?
cells
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targeting siRNA pool (siRNA NT cells) as well as control
non-transfected ECFCs were seeded on fibrin matrices and
simultaneously stimulated with TNF-a and FGF-2 (TF).
siRNA CD34 significantly reduced the mRNA and surface
expression of CD34 as validated by qRT-PCR and FC
(Online resources Supp. Figure 5).
During the course of 2-day stimulation period, the siRNA
NT cells exhibited similar sprouting response as the control,
Fig. 3 Effect of serum supplements on CD34 expression in PB-
ECFCs. a Time course of CD34 induction in PB-ECFCs upon
incubation with media supplemented with different serum supple-
ments during 24-h period. Open circle depicts 10 % NBCS, open
square depicts 10 % NBCS ? 10 % PL, open pointed up triangle
depicts 10 % PL, open diamond depicts 3 % HSA. Data are expressed
as mean ± SEM of n-fold difference of CD34 mRNA levels
compared to the mRNA levels in the cells incubated with
M199 ? 3 % HSA at each time point (HSA, p\ 0.05: # to NBCS,
* to NBCS ? PL, & to PL; PL, p\ 0.05: $ to NBCS, ? to
NBCS ? PL). b Flow cytometry assessment of CD34 expression in
PB-ECFCs cultured in the presence of NBCS or PL. Data are
expressed as a mean ± SEM percentage of cells positive for CD34 in
the cell cultures incubated with CMi medium which contains 10 %
NBCS (open bar) or M199 ? 10 % PL (closed bar). c qRT-PCR
evaluation of CD34 expression in cells incubated with VEGF-A
(25 ng/mL), FGF-2 (10 ng/mL), FV (10 ng/mL FGF-2 ? 25 ng/mL
VEGF-A), HGF (10 ng/mL), and 10 % PL for 24 h prepared in
M199 ? 3 % HSA. Data are expressed as mean ± SEM of n-fold
difference of CD34 gene levels in stimulated cells (closed bars)
normalized to control cells incubated only in M199 ? 3 % HSA
(open bar). d qRT-PCR evaluation of CD34 expression in cells
incubated with VEGF-A (25 ng/mL), FGF-2 (10 ng/mL), HGF
(10 ng/mL), and TNF-a (10 ng/mL) for 24 h prepared in EBM-
2 ? 5 % PL. Data are expressed as mean ± SEM of n-fold difference
of CD34 gene levels in stimulated cells (closed bars) normalized to
control cells incubated only in EBM-2 ? 5 % PL (open bar). e Flow
cytometry evaluation of the effect of VEGF-A (25 ng/mL), FGF-2
(10 ng/mL), HGF (10 ng/mL), and TNF-a (10 ng/mL) for 24 h
prepared in EBM-2 ? 5 % PL on CD34 expression in PB-ECFCs.
Closed bars represent the effect of each of soluble factors prepared in
control medium (open bar) on CD34 expression. Data are expressed
as mean ± SEM of mean fluorescence intensity (MFI) of CD34
antibody fluorescence intensity minus autofluorescence of matched
isotype antibody
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non-transfected cells indicating that the transfection proce-
dure did not alter the sprouting response of PB-ECFCs
(Fig. 6a–c), while the siRNA CD34-transfected cells
exhibited significantly reduced sprout formation (Fig. 6d, e).
In line with an involvement of the fibrinolytic system in
sprouting-associated pericellular proteolysis, the siRNA
u-PA-treated cells completely failed to form sprouting
structures in fibrin matrices sprout formation (Online
resources Supp. Figure 6).
To investigate whether the observed results are related
to the difference in expression of genes associated with tip-
cell phenotype or involved in pericellular proteolysis
accompanying tube formation in fibrin matrices, qRT-PCR
was performed to compare the mRNA levels of set of genes
in siRNA CD34, siRNA NT, and control cells. Silencing of
CD34 in ECFCs did not alter the mRNA levels of tip-cell-
associated genes, while uPA and PAI-1 were moderate
increased in siRNA CD34 cells compared to siRNA NT
cells (Fig. 6f). Therefore, the sprouting response of siRNA
CD34 cells showed that the CD34 protein might indeed
play a role during invasion of fibrin matrices, but its
engagement during the sprouting was independent of the
induction of tip-cell-associated genes in ECFCs.
Discussion
Findings in this study demonstrated that compact colonies
of ECFCs derived from the mononuclear cell fraction of
peripheral blood develop hybrid cellular expression of
Fig. 4 Effect of cell density and proliferation on CD34 expression in
PB-ECFCs. a Proliferation ability of PB-ECFCs seeded at different
cell densities after five (D5, open bars) and six (D6, closed bars)
days. Results represent mean ± SEM of counted cells/cm2 from four
independent experiments each performed with different donor.
b Relation of CD34 surface expression and proliferation in PB-
ECFCs seeded at different cells densities. Flow cytometry evaluation
of the number of CD34? cells in cell cultures established with seeding
PB-ECFCs at different densities after five (D5, open symbols) and six
(D6, closed symbols) days of proliferation. Data represents the
percentage of cells positive for CD34 in the cell cultures established
by seeding 100 (open circle), 500 (open square), 1000 (open pointed
up triangle), and 2000 (open pointed down triangle) cells/cm2 after 5
(open symbols) and 6 (closed symbols) days proliferation plotted
against the number of cells counted at the end of proliferation.
(*p\ 0.05). $indicates p\ 0.05 to 100 cells/cm2 at D5, ? indicates
p\ 0.05 to 500 cells/cm2 at D5; #, *, & indicate p\ 0.05 to 100,
500, and 1000 cells/cm2 at D6; U indicates p\ 0.05 to 2000 cells/cm2
at D5. c Relation of CD34 gene expression and proliferation in PB-
ECFCs seeded at different cells densities. Comparison of mRNA
levels of CD34 at day 5 (D5, open symbols) and day 6 (D6, closed
symbols) in cell cultures established by seeding 100 (open circle), 500
(open square), 1000 (open pointed up triangle), and 2000 (open
pointed down triangle) cells/cm2 of PB-ECFCs plotted to the number
of cells counted at the end of proliferation. Data represent the
mean ± SEM of delta Ct values of CD34 mRNA levels at day 6 (D6,
closed symbols) compared to delta Ct of CD34 mRNA levels at day 5
(D5, open symbols) which served as control
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CD34, i.e., contain CD34? and CD34- cells, which both
express endothelial cell-specific markers. These CD34?
and CD34- ECFCs are not a separate cell lineages but
merely reflect a different but interchangeable phenotype of
endothelial cells. Our data revealed that CD34 is inducible
in the CD34- ECFCs and its regulation depends on cell
density, and serum supplements. Functional assays and
phenotypical characterization of CD34? and CD34-
ECFCs demonstrated that CD34? cells are characterized by
higher sprouting capacity in fibrin matrices and enrichment
of tip-cell-related genes compared to their CD34- coun-
terparts. Silencing of CD34 by siRNA caused improvement
in the barrier function of ECFCs’ monolayers and reduced
the extent of the tubular structures formation by ECFCs,
suggesting a causal role for CD34, but did not affect the
expression of tip-cell-associated genes.
CD34 (re)expression during culture of ECFCs
The re-expression pattern of CD34 in CD34- ECFCs was
in agreement with previous reports on the induction of
CD34 in human umbilical vein endothelial cells (HUVEC)
[22] and hematopoietic stem cells [37]. We observed an
increase in CD34 expression in confluent cells, similar as
but at a much higher level than previously observed in
HUVEC. Furthermore, the present study shows that CD34
was repressed in medium supplemented with NBCS and
human serum, and became re-expressed after exposure of
ECFCs to medium supplemented with human serum
albumin or platelet lysate. Beside by serum, the CD34
expression in ECs might be regulated by pro-angiogenic
factors or inflammatory cytokines [13, 34]. Although the
previous reports suggested that FGF-2 and VEGF-A
Fig. 5 Role of CD34 during maintenance of barrier function in PB-
ECFCs. a Barrier function of control PB-ECFCs (open circle), cells
transfected with non-targeting siRNA (open pointed up triangle), and
cells with CD34 silenced by siRNA (open square) over period of
24 h. Data are expressed as absolute endothelial resistance (Ohm).
b Absolute endothelial resistance of confluent monolayers of PB-
ECFCs of three independent experiments each performed with
different donor. Data of control and siRNA CD34 cells (closed bars)
are normalized to the values of cells transfected with non-targeting
siRNA (open bars) which served as control. c Strength of cell-cell
interaction in confluent monolayers of control cells, cells transfected
with non-targeting siRNA and cells transfected with siRNA CD34.
Data of control and siRNA CD34 cells (closed bars) are normalized
to the values of cells transfected with non-targeting siRNA (open
bars) which served as control. d CD31 and VE-cadherin mRNA
levels in PB-ECFCs transfected with siRNA CD34. Results represent
the mean ± SEM of four independent experiments each performed
with different donor. Open bar depicts the CD34 mRNA levels in
cells transfected with non-targeting siRNA. Closed bars represent the
mRNA levels of CD31 and VE-cadherin in the cells transfected with
siRNA CD34
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reduced or increased the CD34 expression in dermal
microvascular ECs (DMVEC) or HUVEC, respectively
[22, 34], both angiogenic factors as well as HGF did not
alter the CD34 expression in PB-ECFCs cultured in the
presence of either 3 % HSA, 5 % PL or NBCS. This may
be due to the strong suppressive action of NBCS and the
much higher CD34 levels that are reached in platelet
lysate-exposed ECFCs than in primary cultures of HUVEC
and DMVEC. Indeed, according to Barclay et al. [39]
ECFCs belong to the endothelial lineage yet they differ in
their response to environmental conditions. Alternatively,
the effect of growth factors may influence growth rate in
endothelial cells, which it is already very high in ECFCs.
However, Hellwig et al. [38] reported that CD34 regulation
is independent from the induction of proliferation. Fur-
thermore, the state of confluence affects CD34 expression
in ECFCs (this study) as well as in other primary
endothelial cells [13, 34].
Increased sprouting of CD341 ECFCs in fibrin
matrices
Functional assessment of sprouting of CD34? and CD34-
separated cells showed that combined use of FGF-2 and
VEGF induced more spout formation in the fibrin matrices
seeded with CD34? ECFCs compared to cells that lack this
molecule, while both cell fractions proliferated at same
rate. Silencing of CD34 in mixed CD34?/CD34- ECFCs
cultures also reduced formation of endothelial sprouts,
suggesting a causal role of CD34 in enhanced tube for-
mation. Increased sprouting was not related to differences
in fibrinolytic gene profile of CD34? and CD34- fractions
since both cell subsets have comparable basal mRNA
levels of uPA, uPAR, PAI-1, t-PA, and MMP-14. Enrich-
ment of tip-cell-related genes in CD34? ECFCs might
underlie increased sprout formation in fibrin matrices due
to the increased mRNA levels of VEGFR2 or CXCR4,
which are important regulators of the sprouting phase of
angiogenesis [36, 37]. In addition, the CD34 re-expression
in separated CD34- cells was accompanied with increased
levels of tip-cell-related genes suggesting that CD34 can be
used as a marker for selection of ECFCs with distinct
phenotype compared to CD34- selected cells.
Recently Ferreras et al. [31] reported on two separate
types of ECFC colonies, one CD34? with densely growing
cells and a second CD34- type that grows in a more dis-
persed way. These authors concluded that only the CD34-
cells were capable of sprouting when embedded in fibrin or
Fig. 6 CD34 modulates sprouting response of PB-ECFCs in fibrin
matrices. a-d Representative phase contrast pictures of sprout
formation in fibrin matrices. a unstimulated cells; b control, non-
transfected cells; c cells transfected with non-targeting siRNA; d cells
transfected with CD34 siRNA. e Effect of silencing of CD34 in PB-
ECFCs on sprout formation in fibrin matrices. Data are expressed as a
mean ± SEM of mean length of formed sprouts of four independent
experiments each performed with different donor. f mRNA levels of
tip-cell-associated and fibrinolytic genes in PB-ECFCs after silencing
of CD34. Data are expressed as mean ± SEM of n-fold difference of
mRNA levels of depicted genes in the siRNA CD34 transfected cells
(closed bars) compared to the cells transfected with non-targeting
siRNA (open bars) which served as control
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seeded onto Matrigel, while CD34? were not. In contrast to
Ferreras’s report [31], here presented data show that
CD34? ECFCs are able to form tubular endothelial struc-
tures in a fibrin matrix and to an larger extent than CD34-
cells. Furthermore, our data show that CD34? and CD34-
represent both distinct endothelial but interchangeable
phenotypes rather than separate cell lineages in a mixed
population of ECFCs. Our studies do not exclude the
existence of another CD34- population of sparsely grow-
ing late outgrowth cells. We did observe such colonies in
our initial cultures, but these colonies had a poor propa-
gation and could not be cultured further than passage 4 in
our experimental conditions.
It is not excluded that in vitro expansion in platelet
lysate might accentuated the angiogenic phenotype of
CD34? ECFCs. This cell fraction was not only able to
promote sprout formation more than CD34- selected
ECFCs, but also displayed a higher expression of tip-cell-
associated genes. However, as silencing of CD34 did not
affect the expression of tip-cell-associated genes, another
mediator probably controls both CD34 and the other genes.
Our observations on tip-cell gene expression by CD34?
ECFCs are in line with observations of Siemerink et al.
[22] on CD34? HUVEC. However, opposite to the obser-
vations of these latter authors, both CD34? and CD34-
ECFCs proliferated in our conditions at similar rates.
CD34 is involved in regulation of barrier function
in PB-ECFCs
Our observation that CD34 is increased in fully confluent
monolayers of PB-ECFCs and the accumulation of CD34
antigen staining at the cell margins suggests the involve-
ment of this molecule in modulating cell–cell contacts.
Preservation of intact cell–cell contact is an indispensable
component of the barrier function of endothelial mono-
layer. However, silencing of CD34 induced increase in the
strength of cell–cell interaction leading to augmentation of
the barrier function, i.e., reduced permeability, of mono-
layers of PB-ECFCs. The reduction in endothelial barrier
function by CD34 may seem counterintuitive as CD34 is
increased in confluent endothelial cells. However, a similar
effect was observed during mouse embryogenesis where
the negatively charged CD34 molecules induced local
repulsion of cell contacts between sprouting ECs thus
enabling the formation of the lumen of future blood vessel
[36]. Furthermore, in postnatal life, CD34 is expressed by
EC lining the microvasculature in vivo [18]. This antigen,
beside on the cell surface, is also distributed within the
contact area between adjacent endothelial cells especially
on the interdigitating invaginations/processes located close
to the luminal side while the tight junctions appear devoid
of CD34 [18]. Residing at the entry of tight junctions the
CD34 might play a role in the first steps of opening the
cell–cell contact area or in preventing closure of junctions
once they open. During angiogenesis, it might be helpful
for the EC to highly express CD34 on cell surface in order
to reduce the stability of endothelial monolayer thus
ensuring favorable conditions for the initiation of sprout-
ing. Data obtained from sprouting assay with silencing of
CD34 by siRNA support this hypothesis.
CD34 and tip-cell gene expression
CD34? ECFCs formed more sprouts and exhibited higher
mRNA levels of genes associated with tip-cell phenotype
than CD34- ECFCs. This suggests that CD34 in concor-
dance with increased expression of tip-cell genes might be
involved during sprout formation by ECFCs. However, the
silencing of CD34 experiment has shown that—while
CD34 positivity was accompanied by increased expression
of tip cells, the deletion of CD34 by itself was not sufficient
to reduce the expression of these tip-cell genes. This
indicates that CD34 has no causal role in enhancing the
expression of these tip-cell genes in PB-ECFCs. Appar-
ently, while selecting CD34? cells, we also selected for a
hierarchically higher regulator that enhances both CD34
and tip-cell gene expression. This common gene or tran-
scription factor that drives this process in PB-ECFCs is
presently still unknown.
CD341 versus CD342 ECFCs
An interesting observation on CD34 hybrid ECFCs was
made by Lee et al. [40], who suggested that the CD34 hybrid
colonies contained both CD34? ECFCs and CD34- ECFCs,
the latter acting as niche-supporting cells. The existence of
niche-supporting cells fits well within current ideas of
maintenance of stemness [41]. As we obtained 95 % CD34?
cells by cell separation, it is difficult to rule out fully the
possibility that potential niche-supporting cells escaped the
separation. However, we did not observe a difference in the
proliferative capacity of CD34? and CD34- cells, and after
a while both populations finally regressed to the same ratio
CD34?/CD34- cells, a ratio that was mainly influenced by
cell density and culture conditions. The possibility that
CD34? ECFCs can acquire niche-supporting properties
themselves, or that niche-supporting cells may express
temporarily CD34 needs further attention.
Conclusion
This manuscript demonstrates the plasticity and regulation
of CD34 expression in ECFCs cultured from adult human
peripheral blood, as well as the stimulatory role of this
336 Angiogenesis (2016) 19:325–338
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molecule on endothelial tube formation in a 3D-fibrin
matrix. It also pointed to a contribution of CD34 to local
barrier destabilization that may accompany sprouting.
While deletion of CD34 expression by siRNA demon-
strates a causal role of CD34 in improved tube formation—
independent of the regulation of several important tip-cell
genes, selection of CD34? cells from CD34?/CD34-
hybrid ECFC cultures will only have effect when separa-
tion occurs immediately before application of the CD34?
cells. After several days the original hybrid expression
pattern of CD34 will be regained by the subcultured PB-
ECFCs. Notwithstanding, this mixed phenotype still dis-
plays the same sprouting ability and proliferation rate as
the purified CD34? ECFCs.
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